To the best of our knowledge, this is the first study showing that the COX-2 polymorphism could predict toxicity outcomes in patients with advanced stage NSCLC treated with platinum-based chemotherapy. This evidence concerns the gene PTGS2 and non-small cell lung carcinoma.